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Background: Agomelatine is a melatonin receptor agonist and serotonin 5-HT2C receptor 
antagonist indicated for depression in adults. Hepatotoxic reactions like acute liver injury (ALI) 
are an identified risk in the European risk management plan for agomelatine. Hepatoxic reactions 
have been reported for other antidepressants but population studies quantifying these risks are 
scarce. Antidepressants are widely prescribed and users have often risk factors for ALI (e.g., 
metabolic syndrome). 
Objective: The goal was to estimate the risk of ALI associated with agomelatine and other 
antidepressants (fluoxetine, paroxetine, sertraline, escitalopram, mirtazapine, venlafaxine, 
duloxetine, and amitriptyline) when compared with citalopram in routine clinical practice.  
Method: A nested case-control study was conducted using data sources in Denmark, Germany, 
Spain, and Sweden (study period 2009-2014). Three ALI endpoints were defined using ICD 
codes: primary (specific codes) and secondary (all codes) endpoints used only hospital discharge 
codes; the tertiary endpoint included both inpatient and outpatient settings (all codes). Validation 
of endpoints was implemented. Adjusted odds ratios (ORs) and 95% confidence intervals (CIs) 
for current use were estimated for each data source and combined.  
Results: We evaluated 3,238,495 new antidepressant and 74,440 agomelatine users. For the 
primary endpoint, the OR for agomelatine versus citalopram was 0.48 (CI, 0.13-1.71). Results 
were also <1 when no exclusion criteria were applied (OR, 0.37; CI, 0.19-0.74), when all 
exclusion criteria except alcohol and drug abuse were applied (OR, 0.47; CI, 0.20-1.07), and for 






































































Regarding other antidepressants versus citalopram, most OR point estimates were also below 
one, although with varying widths of the 95% CIs. The result of the tertiary endpoint and the 
sensitivity analyses of the primary endpoint were the most precise. 
Conclusion: In this study using citalopram as a comparator, agomelatine was not associated with 
an increased risk of ALI hospitalisation. The results for agomelatine should be interpreted in the 
context of the European risk minimisation measures in place. Those measures may have induced 
selective prescribing and could explain the lower risk of ALI for agomelatine when compared 
with citalopram. Most other antidepressants evaluated had ORs suggesting a lower risk than 
citalopram, but additional studies are required to confirm or refute these results.  
The study protocol was registered in The European Medicines Agency electronic Register of 
Post-Authorisation Studies (EU PAS Register # EUPAS10446). 
KEY POINTS  
 Agomelatine did not increase the risk of hospitalisation due to acute liver injury (ALI) in 
the studied populations when compared to citalopram. Results were robust in multiple 
sensitivity analyses. 
 In the populations studied, risk minimisation measures were in place and may have 
contributed to the lower risk found for agomelatine when compared with citalopram. 
Thus, compliance with relevant contra-indications, precautions of use, and biological 






































































 Of the other antidepressants, sertraline, escitalopram, mirtazapine, venlafaxine, 










































































Agomelatine (Valdoxan, Thymanax) is a melatonin receptor agonist and serotonin 5-HT2C 
antagonist indicated for major depressive episodes in adults [1]. Hepatotoxic reactions are an 
identified risk of agomelatine included in the European risk management plan and the drug label, 
which recommend that aminotransferase levels are checked before treatment initiation and then 
after 3, 6, 12, and 24 weeks and following a dose increase [2]. While other antidepressant drugs 
used in Europe do not have similar recommendations, hepatotoxic reactions do occur with some 
of them. The severity and frequency of those reactions vary among antidepressants. According to 
studies based only on case reports, they seem to be more common and severe with use of 
tricyclic antidepressants and monoamine oxidase inhibitors than with use of serotonin 
norepinephrine reuptake inhibitors and selective serotonin reuptake inhibitors (0.5%-1%) [3, 4]. 
Acute liver (ALI) injury refers to the sudden appearance of liver test abnormalities and 
encompasses a spectrum of clinical diseases ranging from mild biochemical abnormalities to 
acute liver failure [5]. When known causes of ALI have been ruled out and criteria for causality 
of a specific drug are met, the term drug-induced liver injury is used instead [5, 6]. Standardised 
definitions of ALI for use in epidemiologic studies have been proposed [5, 7] and the incidence 
of ALI related to antidepressant use requiring hospitalisation has been estimated to be 1-4 cases 
per 100,000 patients-years [3]. 
Antidepressant drugs are currently among the most widely used drugs in Western countries [8, 9] 






































































dependence and metabolic syndrome [10-12]. Other risk factors for ALI include older age, 
female sex, concurrent use of hepatotoxic medications, previous acute and chronic hepatic, 
biliary, and pancreatic conditions, malnutrition, HIV infection, and chronic inflammatory 
diseases [13, 14].  
Two previous studies on the risk of ALI associated with the use of duloxetine have been 
conducted using Ingenix Research Data Mart and in Optum Research Database in the United 
States [15, 16], suggesting an increased risk of ALI with duloxetine when compared with 
venlafaxine [15, 16] and selective serotonin reuptake inhibitors [15].  
The primary goal of this post-authorisation safety study [17], using a nested case-control 
analysis, was to evaluate the risk of hospitalisation for ALI associated with agomelatine and 
eight other antidepressant drugs as used in current medical practice compared with citalopram.  
2. METHODS 
2.1. Study Design and Study Period 
 In brief, we conducted a large, multinational, retrospective longitudinal cohort and nested 
case-control study comparing new users of agomelatine (main exposure of interest) and new 
users of eight other study antidepressants with new users of citalopram (common reference 
group). Citalopram was selected as a comparator because it was the most commonly used 
antidepressant in three of the four countries and, according to literature reviews available at the 
time of writing the protocol, was among the antidepressants with the least potential for 
hepatotoxicity [3, 4]. The other antidepressants were selected because they were commonly used 






































































in the respective country (in 2009 or 2010) and ended with the last year for which data were 
available in each data source (2013 or 2014). The full study protocol can be accessed at the 
European Union Electronic Register of Post-Authorisation Studies (EU PAS Register # 
EUPAS10446) [18].  
2.2. Setting 
This study was conducted in automated health databases in four countries: Spain (SIDIAP 
[Information System for Research in Primary Care] [19] and EpiChron Cohort [EpiChron 
Research Group on Chronic Diseases]) [20], Germany (GePaRD [German 
Pharmacoepidemiological Research Database]) [21-23] and the national registers in Denmark 
[24-30] and Sweden [30-32]. Characteristics of the databases are described in Online Resource 1. 
2.3. Study Population 
The study cohort included all individuals aged 18 years or older at the date of the first-recorded 
prescription fill of any of the study antidepressants during the study period(s) who (1) had not 
received a prescription fill for the same study antidepressant within the prior 12 months (new 
users) and (2) had at least 12 months of continuous enrolment in the data source before the first 
prescription fill defining cohort entry. Thus, one patient could contribute to several 
antidepressant cohorts if eligibility criteria were fulfilled. For women, an additional eligibility 
criterion was absence of pregnancy at the start date of antidepressant use. Patients with a history 
of liver disease or risk factors for liver disease (e.g., alcohol and drug abuse and dependence-
related disorders), chronic biliary or pancreatic disease, malignancy, or other life-threatening 
conditions (e.g., cancer, HIV infection) were excluded from the study cohort (see Online 






































































2.4. Endpoints Ascertainment: Selection of Cases and Controls 
The primary endpoint was ascertained in all data sources and defined as any patient with a 
specific hospital discharge diagnosis code of ALI from either the International Classification of 
Diseases, 9th Revision (ICD-9) or the International Statistical Classification of Diseases and 
Related Health Problems, 10th Revision (ICD-100F). 
The secondary endpoint was defined as validated cases of ALI (see below) identified with 
specific and nonspecific1 hospital discharge diagnosis codes and was evaluated only in Spain 
(EpiChron and SIDIAP) and Denmark. 
The exploratory tertiary endpoint was assessed based on specific and nonspecific codes 
identified in both hospital and outpatient settings and was evaluated in all data sources regardless 
of whether validation was feasible. A sensitivity analysis restricted to validated cases was 
conducted in the three data sources in which validation was implemented. The list of specific and 
nonspecific codes is included in the supplemental material (Online Resource 3). The list of codes 
was adapted to the country-specific ICD classification system used. The investigators in each 
country reviewed the codes list and made small adaptations when necessary. Additionally, local 
clinicians were consulted. 
Potential cases of ALI identified with specific and nonspecific codes were confirmed by 
validation processes according to the definition criteria established by an international expert 
working group [5]. The definition criteria are based on increases in the levels of alanine 
aminotransferase (ALT), alkaline phosphatase (ALP), and bilirubin over the upper limit of 
                                                 
1 The term specific and nonspecific are used here to indicate groups of codes that have in previous studies showed more (specific) 






































































normality (ULN) with less than 1 year of persistence: (≥ 5 x ULN ALT) or (≥ 2 x ULN ALP) or 
(≥ 3 x ULN ALT and > 2 x ULN bilirubin). This study was not designed to evaluate causality at 
the individual level to ascertain whether a specific case with phenotypical ALI had drug-induced 
liver injury or not. Rather, the study was designed to examine the potential causal role of 
agomelatine and other antidepressants when compared with citalopram in the development of 
ALI at the population level. Thus, no formal evaluations using the Roussel Uclaf Causality 
Assessment Method (RUCAM) [33] were implemented at the individual case level. Potential 
cases were adjudicated by trained clinicians based on review of information abstracted from 
medical records. This information included timing and results of liver enzymes and information 
on presence or absence of excluding conditions [34]. Thus, the clinical reviewers were 
adjudicating whether the individual potential cases met the study definition criteria of ALI and 
whether excluding conditions were present, not whether they met criteria for causality between 
antidepressant use and liver injury. Validity of the electronic algorithms based on diagnosis 
codes used in the secondary and tertiary endpoints was assessed by calculating the positive 
predictive value (PPV), defined as the probability that a patient classified as a potential case was 
a confirmed case of ALI based on the reviewed data (excluding nonevaluable cases from the 
denominator). 
In Germany, a companion external validation study (ALIVAL) of the ICD discharge and 
outpatient diagnosis codes for ALI was conducted in a German hospital to estimate the PPV of 
algorithms used in the GePaRD data source to identify potential cases of the primary and tertiary 






































































In the case-control analysis, all ALI cases identified according to the definition of each endpoint 
in the study cohort were included as cases. Controls were selected from the study cohort using 
density sampling. Up to 20 controls per case were randomly selected from the risk set of each 
case. Controls were matched to cases on age and sex, index date, and calendar year of study 
(cohort) entry. 
2.5. Exposure Variables and Confounding Factors 
Time at risk was defined according to the days of supply of each prescription fill plus a period of 
40 days. Days of supply were the assumed number of days of treatment associated with each 
prescription fill. The period of 40 days was added to account for stockpiling and less than perfect 
adherence [35]. 
In the nested case-control main analysis, use status was classified for each patient and each 
antidepressant into four mutually exclusive categories according to time at risk of the most recent 
prescription fill received on or before the index date: 
 Current use: when the time at risk of the most recent prescription fill overlapped the 
index date 
 Recent use: when the time at risk ended within 60 days before the index date 
 Past use: when the time at risk ended more than 60 days before the index date 
 Nonuse: when there was no prescription fill of the study drug under consideration before 
the index date 
Confounding factors were those related to the risk of ALI [13, 14, 36] and to exposure to 






































































(through matching); acute alcohol intoxication; obesity; other components of metabolic 
syndrome (hypertension and dyslipidaemia); diabetes; inflammatory bowel disease; preexisting 
comorbidity measured by the Charlson Comorbidity Index; acute biliary and pancreatic disease; 
peptic ulcer disease; rheumatic diseases; concurrent use of hepatoxic drugs (list of drugs 
available in Online Resource 4); concurrent use of other antidepressants (different from study 
antidepressants); number of liver tests performed; and health care resource utilization measures 
were considered potential risk factors or confounders.  
2.6. Statistical Analyses 
Crude and adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for ALI for current use 
of each study antidepressant were estimated using conditional logistic regression models with 
current use of citalopram as the reference category (main analysis). 
Crude ORs (and 95% CIs) were estimated including only the exposure variables in the 
conditional logistic regression model. Due to the matching of cases and controls and conditional 
analyses, these crude ORs were adjusted by age, sex, and calendar year at study entry but were 
referred to as crude ORs regarding the rest of the confounders. Because of the low number of 
cases in some data sources, the original exposure variables had to be reclassified into fewer 
categories (i.e., current use vs. other) and in each of the separate logistical models comparing 
citalopram with each one of the other antidepressants, a new single exposure variable was 
created to classify current use status of the two antidepressants being compared. 
Important risk factors and potential confounders were a priori included in the models. Other 
potential confounders were tested in a backward elimination process [37] to avoid problems with 






































































confounders was evaluated at any time before the index date, but some variables (e.g., concurrent 
use of hepatotoxic drugs) were evaluated just 6 months before the index date. In Online Resource 
5, we include a table providing additional details on the timing of evaluation for the different 
potential confounders. 
For each of the three study endpoints, meta-analysis was used to combine the adjusted OR 
estimates obtained from the nested case-control analysis in the different data sources. Combined 
ORs and 95% CIs for ALI were produced first using random-effects models [38]. To assess 
heterogeneity in the meta-analysis, the I2 statistic was employed. When results were 
homogeneous across databases, fixed-effects models were used, and these results were presented 
in the results tables. When the I2 test statistic was 30% or higher for any of the antidepressants, 
random-effects models were presented for all antidepressants. Forest plots were created for each 
analysis table to display the adjusted combined and data source–specific results. When no events 
were observed in some of the data sources, we included only the results from data sources with 
observed events. 
To check the robustness of the results, several planned sensitivity analyses were performed: the 
effect of adding 15 days or 60 days (instead of 40 days) to the days of supply of the most recent 
prescription before the index date was explored, the effect of recent and past use of each study 
antidepressant was compared with current use of citalopram; switching and multiple current use 
were compared with current single use of citalopram, and analysis restricted to cases without 
known causes of ALI were conducted. The implementation of those sensitivity analyses was 
limited in most data sources by the limited number of cases. In addition, two post hoc sensitivity 






































































one, no exclusion criteria were implemented, and in the other, all study exclusion criteria were 
applied except those related to alcohol use disorder and drug abuse. 
3. RESULTS 
A total of 3,238,495 new users of antidepressants (EpiChron, n = 185,628; SIDIAP, n = 203,101; 
the GePaRD, n = 817,072; the Danish National Health Registers, n = 664,205; and the Swedish 
National Registers in Sweden, n = 1,368,489) were included in the main analysis, of which 
74,440 were new users of agomelatine (Table 1). Agomelatine, the most recently launched of the 
studied antidepressants was the least dispensed antidepressant in the study. A table presenting the 
distribution of the main confounder factors at cohort entry in each data source is included in 
Online Resource 6. 
In the main analysis, a total of 472 cases were identified for the ALI primary endpoint (specific 
hospital discharge codes), ranging from 19 (SIDIAP) to 170 (Danish National Health Registers).  
Online Resource 7 presents the number of cases and controls in each data source and the 
association between potential confounders and the ALI primary endpoint in the multivariable 
adjusted models, which was different in the five data sources. Table 2 displays the number of 
new users in each antidepressant cohort and the number of cases and controls by endpoint, 
antidepressant cohort, and overall numbers. 
3.1. Primary Endpoint 
Online Resource 8 presents the age- and sex-standardised incidence rates of ALI for the primary 
endpoint by data source and studied antidepressant. The estimates were imprecise, ranged from 0 






































































described previously in the literature [39]. The PPVs for the specific codes used to identify the 
primary endpoint ranged from 60.0% (SIDIAP) to 84.2% (EpiChron) in the study data sources, 
and the PPV was 62.7% in the external validation study in Germany (ALIVAL).  
Results of the case-control analyses for the current use of agomelatine compared with current use 
of citalopram are presented in Table 3. 
Current use of agomelatine compared with current use of citalopram yielded ORs below 1.00 in 
all data sources with cases (no cases under current use of agomelatine were identified in SIDIAP 
and Sweden) with imprecise estimates. The combined (meta-analysis) adjusted OR for current 
use of agomelatine compared with citalopram was 0.48 (95% CI, 0.13-1.71). 
In the post hoc sensitivity analysis without exclusions (including 4,833,774 new users of 
antidepressants, of which 117,240 were new users of agomelatine), more cases were identified, 
and therefore, the OR estimates were more precise and in line with the main analysis. The 
combined adjusted OR for current use of agomelatine compared with citalopram was 0.37 
(95% CI, 0.19-0.74). The point estimates were homogeneous across all data sources for the 
sensitivity analysis without exclusions. 
In the post hoc sensitivity analysis including patients with disorders related to alcohol and drug 
abuse (3,531,529 new users of antidepressants, of which 84,210 were new users of agomelatine), 
the combined adjusted OR for current use of agomelatine compared with citalopram was 0.47 
(95% CI, 0.20-1.07). The individual point estimates from the different data sources were less 
homogeneous: both EpiChron and SIDIAP, which had the smallest agomelatine cohorts, showed 






































































Figure 1 presents the combined results for current use of each antidepressant in the main analysis 
and the two post hoc sensitivity analyses for the primary endpoint. For all antidepressants except 
fluoxetine and paroxetine, the combined point estimates were less than 1.00 in the main analysis. 
The 95% CIs were more imprecise in the main analysis than in the two post hoc sensitivity 
analyses, in which all antidepressants had ORs below 1.00 when compared with citalopram.  
Results of the planned sensitivity analyses (including the ones assessing different exposure 
definitions and analysis excluding known causes of ALI) for agomelatine and the other 
antidepressants were, in general, consistent with the main analysis and produced combined OR 
point estimates for agomelatine below 1.00 for current use (data not shown). Results for all 
antidepressants, combined and in each individual data source, and for the three endpoints are 
available in the online supplemental material (Online Resources 9-11) 
3.2. Secondary Endpoint 
The secondary endpoint included only cases that had been confirmed after validation, which 
resulted in a lower number of events than for the primary endpoint. A total of 178 confirmed 
cases (150 in Denmark, 20 in EpiChron, 8 in SIDIAP) and 3,540 controls was identified. 
Confirmed cases during current use of agomelatine were identified in Denmark only; the 
adjusted OR estimate for current use was 0.40 (95% CI, 0.05-3.11). For the other antidepressants 
when compared with citalopram, most combined OR point estimates were less than one except 






































































3.3. Tertiary Endpoint 
Overall, there were 17,118 cases of the tertiary study endpoint and 342,070 controls. The 
GePaRD had overall the largest number of cases (11,917), followed by SIDIAP (2,826), Sweden 
(1,099), Denmark (1,088), and EpiChron (268). The PPV of the tertiary endpoint cases was low 
in all data sources but especially in SIDIAP (7.7%). The highest PPVs (47.0%) were found in 
Denmark and the ALIVAL external study (Germany, 45.1%). In EpiChron, the PPV was 25.4%. 
In Sweden, no validation of cases was implemented. 
For this tertiary endpoint, the combined estimate for agomelatine for current use was 0.79 
(95% CI, 0.50-1.25). The results were heterogeneous (I2 = 71% indicating the presence of strong 
heterogeneity). The individual data source–adjusted ORs for current use of agomelatine were 
also below 1.00, except in the GePaRD, and ranged from 0.36 (95% CI, 0.11-1.25) in Sweden to 
0.95 (95% CI, 0.33-2.75) in EpiChron. In the GePaRD, the adjusted OR was 1.24 (95% CI, 1.07-
1.42) and contrasted with the ORs observed in Denmark and Sweden, which were approximately 
0.5 (Online Resource 12). In Denmark, the adjusted OR estimate for current use of agomelatine 
was 0.44 (95% CI, 0.22-0.87). In the sensitivity analysis that included only confirmed cases 
(confirmed cases available only in Denmark; see Online Resources 13) of the tertiary endpoint, 
the OR was 0.75 (95% CI, 0.17-3.22). 
For the other antidepressants (Online Resource 11), all combined OR estimates were between 
0.94 and 1.11. There was an indication of heterogeneity for mirtazapine, duloxetine, and 
amitriptyline (I2 > 50%, indicating at least moderate heterogeneity). The combined OR 95% CIs 






































































analysis that included only confirmed cases (Online Resource 13), all combined OR estimates 
were below one except for duloxetine (OR, 1.03; 95% CI, 0.60-1.79). 
4. DISCUSSION 
Use of agomelatine was not associated with higher risk of ALI hospitalisation compared with use 
of citalopram in a large cohort comprising 3.2 million new users of antidepressants in five 
populations from four countries: Spain, Denmark, Sweden, and Germany. Although precision of 
the combined risk estimates was low for the primary endpoint, the results were similar and more 
precise in the unrestricted sensitivity analyses and consistent both with the other sensitivity 
analyses and with the results of the other two endpoints considered. In the combined analysis, no 
increase in risk was observed in populations including alcoholic patients or with other various 
risk factors. For the other antidepressants, most presented ORs below 1 except for fluoxetine and 
paroxetine. Further, as for agomelatine, similar results were obtained when using other outcome 
definitions, that is, the secondary and tertiary endpoint. 
The estimates of risk associated with agomelatine use in this study are consistent with those from 
a recent cohort study funded by the French National Agency for Medicines and Health Products 
Safety and conducted using the French Health Insurance database. This study did not find an 
increased risk of severe liver injury associated with the use of agomelatine compared with use of 
selective serotonin reuptake inhibitors (adjusted hazard ratio, 1.07; 95% CI, 0.51-2.23) [40]. 
In our study, analyses of most study antidepressants yielded ORs of ALI hospitalisation lower 
than 1.00 when compared with citalopram in the combined analyses for all endpoints. Since we 






































































in the direction of this association across antidepressants was unexpected. However, the 
limitations discussed hereafter, particularly those related to the low number of cases, preclude 
drawing definite conclusions. Citalopram is, in many countries, one of the first-line treatment 
options and is considered one of the safest antidepressants and could be selectively prescribed to 
those cases at the highest risk of ALI, which could potentially result in confounding by 
indication, but other antidepressants in this study share a similar drug prescription pattern. 
Although citalopram has been considered safe when compared with other antidepressants in 
analyses of spontaneous reports of adverse drug reactions [41, 42] and in reviews of published 
clinical data [3], two epidemiological studies found an increased risk of drug-induced liver injury 
associated with citalopram use [43, 44]. Of note, the French study [40] did not find any relevant 
differences in risk between selective serotonin reuptake inhibitors, serotonin and noradrenaline 
reuptake inhibitors, and other antidepressants (e.g., agomelatine). 
As in any study in automated data, misclassification of exposure status, occurrence of incident 
events, and the covariates to be included in the multivariable models is possible. In this study, 
this would likely have resulted in nondifferential misclassification of the endpoints, potentially 
biasing the estimates towards unity. However, small differences in misclassification of the 
exposure or the disease may result in bias towards or away from unity in an unpredictable 
manner [45]. 
To minimise misclassification of endpoints, specific codes were used for the primary endpoint, 
and validation of the secondary endpoint that included nonspecific codes was implemented. 
Validation of potential cases was implemented in a sensitivity analysis of the tertiary endpoint. 






































































underlying health care systems (e.g., body mass index was available in data sources with access 
to primary care data), which may explain some of the differences observed in the prevalence of 
some clinical features, as well as the differences observed across the study data sources in the 
PPVs and some OR estimates. For the primary endpoint, the PPVs of the specific codes ranged 
from 60% in SIDIAP to 84% in EpiChron and were consistent or higher than the estimates from 
previous studies [46-53]. In SIDIAP, access to hospital medical records was not available and 
PPVs would have probably been higher otherwise. Some PPV estimates were imprecise, 
especially in SIDIAP and in the ALIVAL study, and differences between data sources could be 
also explained by random error. Importantly, however, the results of the secondary endpoint that 
included only confirmed cases were consistent with the results of the primary endpoint. 
As already mentioned the number of identified events of the primary and secondary endpoint 
was limited among agomelatine users and users of other antidepressants. For the tertiary 
endpoint, the number of cases was much higher (especially in the GePaRD and SIDIAP), yet the 
low PPVs observed for this endpoint definition limit the interpretation of these results in the 
analysis that included unconfirmed cases. 
Patients taking agomelatine undergo routine liver enzyme monitoring as a risk minimisation 
measure. Therefore, patients at known risk of developing ALI may not have been prescribed 
agents (such as agomelatine) that are thought to be associated with an increased risk of ALI. 
Moreover, detection of liver enzyme elevations may be more likely in this group and prevent 
patients from starting treatment with agomelatine, or if agomelatine treatment has been started, 
treatment may be stopped earlier or cases of liver injury may be detected more frequently and 






































































studies using data from routine clinical practice, these scenarios could lead to selective 
prescribing, surveillance bias, or both. Selective prescribing, i.e., the less frequent prescription of 
agomelatine to patients with known risk factors for ALI or with evidence of existing liver 
damage measured by liver function tests, would shift the results in favour of agomelatine and 
lead to an apparently lower risk of ALI among agomelatine new users when compared with new 
users of citalopram. The comparison of the different antidepressant cohorts in the main analysis 
and in the sensitivity analysis including patients with known risk factors (data not shown) do not 
seem to indicate that agomelatine is less prescribed among patients with known risk factors (e.g., 
chronic liver conditions). Moreover, the results of the sensitivity analysis are consistent with the 
results of the main analysis, the latter excluding patients at risk of ALI, and show an odds ratio 
estimate also below one and with larger precision. However, because of the risk minimisation 
measures in place, selective prescribing could still take place (e.g., agomelatine would not be 
prescribed to those patients with abnormal liver tests or those with contraindications and 
precautions of use according to approved label) and this cannot be assessed with the data 
available. Thus, it is plausible that selective prescribing may have influenced the results of the 
study, which need to be interpreted in the context of the risk minimisation measures in place for 
agomelatine. In fact, our results suggest that the risk minimization measures in place for 
agomelatine are effective. 
Similarly, surveillance bias is unlikely to have had a large impact on the reported estimates for 
the primary and secondary endpoints, as these included only hospitalised and thereby more 
severe cases. In the combined results, no risk increase was found for the tertiary endpoint, which 
was in principle more sensitive to surveillance bias and misclassification than the primary and 






































































context of low PPVs, nondifferential misclassification would produce bias towards seeing no 
association.  
The possibility of residual confounding cannot be discarded. As mentioned, the amount of 
information on some potential confounders (e.g., obesity) was limited in some of the data 
sources. Moreover, the limited number of identified ALI cases for the primary and secondary 
endpoints impacted the multivariable logistic regression strategy. To ensure a sufficient case-to-
covariate ratio, the number of covariates and number of categories for categorical covariates 
included in the models had to be minimised. This resulted in more statistically stable models, but 
it may have increased the risk of residual confounding. Nevertheless, the restrictive cohort 
inclusion criteria implemented likely excluded most of the key potential confounders associated 
with ALI. Moreover, the post hoc analysis that did not impose any exclusion criteria resulted in a 
much larger number of new users of agomelatine (117,240) and of other antidepressants 
(4.8 million overall) and yielded more precise OR estimates for the primary endpoint that were 
consistent with those obtained in the main analysis. Also, control of confounding via 
multivariable models in those analyses did not have the limitations encountered in the main 
analysis of the primary endpoint. 
The study had important strengths, first of which is that it evaluated more than 3 million (almost 
5 million in one of the sensitivity analyses) new users of antidepressants and is the first study of 
this size to include also a validation component of the cases identified. Second, inclusion of 
multiple independent data sources and populations from different countries allowed evaluation of 
the consistency of the findings across five different, heterogeneous, automated, health care data 






































































value and yielding a varying number of cases created different perspectives for interpreting the 
study results. 
5. CONCLUSION 
The results of this study do not suggest that risk of hospitalised ALI with use of agomelatine 
(compared with use of citalopram) constitutes a public health problem, at least among patient 
populations in health care systems with prescription patterns and risk minimisation measures 
similar to those in this study. Thus, it is important to keep in place and comply with the existing 
risk minimisation measures for agomelatine, which our results suggest are effective in preventing 
ALI among users of agomelatine. When compared with citalopram, most antidepressants had OR 
point estimates less than 1.00 for hospitalised ALI. However, uncontrolled sources of bias could 
explain the results, and specific studies to investigate this potential association of citalopram with 
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TABLE 1. Summary of the Cohort Attrition for Users of Study Antidepressants 
 













































































































































































































































a Total number of users before applying eligibility and exclusion criteria. 






































































TABLE 2. Number of New Users in Each Antidepressant Cohort and Number of Cases and Controls by Study 
Endpoint and Antidepressant Cohort 
 
 
Primary Endpoint (Specific 
Hospital Discharge Codes) 
Secondary Endpoint (Specific 
and Non-Specific Hospital 
Discharge Codes—Only 
Validated Cases Included) 
Tertiary Endpoint (Specific and 
Non-Specific Hospital Discharge 
and Outpatient Codes)  
 
New Users,  
N (%)a 
[n = 3,238,495] 
Number of  
Casesb (%)  
[n = 472] 
Number of  
Controlsc (%)  
[n = 9,438] 
Number of  
Casesb (%)  
 [n = 178] 
Number of  
Controlsc (%)  
 [n = 3,540] 
Number of  
Casesb (%)  
 [n = 17,118] 
Number of  
Controlsc (%)  
 [n = 342,070] 
Citalopram 782,812 (24.2%) 111 (23.5%) 1,790 (19.0%) 45 (25.3%) 806 (22.8%) 2,667 (15.6%) 53,296 (15.6%) 
Agomelatine 74,440 (2.3%) 2 (0.4%) 112 (1.2%) n < 5 59 (1.7%) 284 (1.7%) 4,771 (1.4%) 
Fluoxetine 150,569 (4.6%) 9 (1.9%) 217 (2.3%) n < 5 51 (1.4%) 547 (3.2%) 10,974 (3.2%) 
Paroxetine 125,595 (3.9%) 7 (1.5%) 201 (2.1%) 1 (0.6%) 72 (2.0%) 590 (3.4%) 10,853 (3.2%) 
Sertraline 479,631 (14.8%) 41 (8.7%) 805 (8.5%) 13 (7.3%) 314 (8.9%) 775 (4.5%) 15,412 (4.5%) 
Escitalopram 260,367 (8.0%) 25 (5.3%) 490 (5.2%) 16 (9.0%) 255 (7.2%) 603 (3.5%) 12,902 (3.8%) 
Mirtazapine 556,888 (17.2%) 41 (8.7%) 967 (10.2%) 18 (10.1%) 458 (12.9%) 1,348 (7.9%) 23,433 (6.9%) 
Venlafaxine 271,032 (8.4%) 35 (7.4%) 637 (6.7%) 7 (3.9%) 254 (7.2%) 1,178 (6.9%) 19,900 (5.8%) 
Duloxetine 158,686 (4.9%) 11 (2.3%) 322 (3.4%) 2 (1.1%) 122 (3.4%) 502 (2.9%) 9,297 (2.7%) 
Amitriptyline 378,475 (11.7%) 22 (4.7%) 467 (4.9%) 3 (1.7%) 125 (3.5%) 1,084 (6.3%) 17,644 (5.2%) 
Note: Percentages in each cell were obtained from the total number of ALI cases or controls included in the column header. 
Note: Due to data protection policies, the exact number of cases could not be provided when the number of cases was less than 5. 
a Percentages in this column are row percentages of the total number of all users 






































































c This number represents the total number of controls. Controls in the body of the table are only those with current use of the antidepressant. 
TABLE 3. Results for the Primary Endpoint and Current Use (Agomelatine vs. Citalopram) in Each Data Source 
and Combined in the Main Analysis and the Two Post Hoc Sensitivity Analysesa 
 
EpiChron  














OR (95% CI) 
Combined  
OR (95% CI) 










Sensitivity post hoc analyses 












Exclusion criteria applied, except alcohol 













ALI = acute liver injury; CI = confidence interval; OR = odds ratio; PRAC = Pharmacovigilance Risk Assessment Committee (of the European Medicines Agency); 
SIDIAP = Information System for Research in Primary Care; GePaRD = German Pharmacoepidemiological Research Database. 
a Adjusted for confounding factors; the list of confounders differed by data source. The following confounders were included in most analyses: obesity, 
hyperlipidaemia and hypertriglyceridaemia, diabetes, hypertension, indication of treatment with antidepressants for major depression, indication of treatment with 
antidepressants for anxiety disorders, indication of treatment with antidepressants for other mental and behavioural disorders, Charlson Comorbidity Index, 
number of liver tests performed, concurrent use of hepatotoxic drugs, and concurrent use of other antidepressants. 







































































Fig 1 Current Use Combined Adjusted Estimates for All Antidepressants (Primary 
Endpoint Main and Two Sensitivity Post Hoc Analyses Removing Exclusion 
Conditions)a 
a Odds ratio estimates were adjusted for confounding factors. The list of confounders differed by data source and type 
of analysis (main vs. sensitive analyses). The following confounders were included in most analyses: obesity, 
hyperlipidaemia and hypertriglyceridaemia, diabetes, hypertension, indication of treatment with antidepressants for 
major depression, indication of treatment with antidepressants for anxiety disorders, indication of treatment with 
antidepressants for other mental and behavioural disorders, Charlson Comorbidity Index, number of liver tests 
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Exclusion criteria applied, 
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